Skip to main content

Table 2 Vaccines against SARS-CoV-2 given from the time they became available and through 2022. The study population of people who use drugs (PWUD) compared to the general population

From: Seroprevalence of SARS-CoV-2 and humoral immune responses to COVID-19 mRNA vaccines among people who use drugs - in the light of tailored mitigating strategies

 

PWUD

General population*

N = 98

Age group 18–64 years

N = 3 364 266

Total population

N = 5 487 875

n (%)

95% CI

%

%

Lower

Upper

Dose 1

83 (84)

0.77

0.91

89%

77%

Dose 2

73 (74)

0.65

0.83

86%

72%

Dose 3

31 (31)

0.22

0.40

60%

53%

Dose 4

3 (3)

-0.00

0.06

5%

16%

  1. Study participants all received COVID-19 mRNA vaccines
  2. N = number of population and study participants
  3. n = number of study participants receiving vaccine against SARS-CoV-2
  4. % = per cent
  5. 95% CI = 95% confidence interval. Considering the very large sample size of the general population samples, giving a very narrow 95% CI, only the point estimates are provided for these prevalences
  6. * Data first published in the weekly report no 52/2022 by the Norwegian Institute of Public Health [30]
Back to article page

Harm Reduction Journal

ISSN: 1477-7517